February 27, 2012
Biodesix Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced a collaboration with Kadmon Corporation, LLC, to explore the utility of Biodesix’ VeriStrat® test in a Phase 3 non-small cell lung cancer (NSCLC) study of Kadmon’s KD019, a reversible tyrosine kinase inhibitor (TKI) targeting EGFR, HER2, VEGFR2 & 3, and SRC.
The Phase 3 ... Read more
February 22, 2012
Biodesix, Inc., a fully integrated molecular diagnostics company dedicated to personalizing medicine, today announced the relocation of their corporate headquarters from Broomfield, Colorado to Boulder, Colorado. The new location at 2970 Wilderness Place, Suite 100, Boulder, CO 80301 will be able to accommodate Company’s future growth. Biodesix Research & Development locations, as well as the ... Read more
January 30, 2012
Biodesix, Inc., a fully integrated molecular diagnostics company dedicated to personalizing medicine, today announced the issuance of three additional patents. The U.S. Patent & Trademark Office (PTO) granted two new patents which provide intellectual property protection for methods relating to the Company’s products and technology. In addition, the European Patent Office granted to Biodesix a patent providing coverage ... Read more
December 7, 2011
Results from the VeriStrat retrospective analysis of the Phase III trial, EGF30008, were presented today at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium. The EGF30008 study compared Femara® plus placebo to Femara plus Tykerb® in 1st line, hormone receptor positive, advanced breast cancer patients. The study included both Her2 positive and Her2 negative patients. Results ... Read more
December 5, 2011
Biodesix Inc. a fully integrated molecular diagnostic company dedicated to personalizing medicine, is pleased to be the recipient of Frost & Sullivan’s 2011 North American Cancer Diagnostics Product Differentiation Excellence Award.
The Product Differentiation Excellence Award is a prestigious recognition of Biodesix’ accomplishments in the cancer diagnostics industry, and of their first product, VeriStrat®. VeriStrat is a serum proteomic test ... Read more
November 22, 2011
Biodesix today announced that results from a prospectively designed, retrospective analysis of serum samples from the phase III study, EGF30008, will be presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). The purpose of the study was to evaluate the ability of the diagnostic test, VeriStrat, to predict patient outcomes following treatment with either ... Read more
November 2, 2011
Biodesix Inc, a fully integrated molecular diagnostic company dedicated to personalizing medicine, announced today the publication of “Changes in plasma mass-spectral (VeriStrat) profile in course of treatment of NSCLC patients with EGFR-TKIs” by Lazzari, et al. in the November issue of the Journal of Thoracic Oncology, currently available online.
The study retrospectively evaluated VeriStrat classification prior to ... Read more
October 24, 2011
WHAT: BioConference Live has selected Biodesix to present at the 5th annual Life Sciences conference, taking place online on October 26-27. Biodesix, based in Broomfield, CO, is a fully integrated molecular diagnostic company developing products for personalized medicine that improve clinical decision making. Paul Beresford, Biodesix Vice President, will discuss an alternative strategy for rapid companion diagnostic ... Read more
October 18, 2011
Data presented at the 10th International Kidney Cancer Symposium being held in Chicago, IL show that the pretreatment blood-based test, VeriStrat, was able to stratify renal cell carcinoma (RCC) patients treated with a combination of two targeted therapies, sunitinib (Sutent®) and erlotinib (Tarceva®), by survival outcomes. Patients who tested VeriStrat Good had significantly longer progression ... Read more
October 13, 2011
Biodesix Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced the initiation of two strategic partnerships that will provide cancer patients greater and more convenient options for completing VeriStrat testing. VeriStrat® is a blood-based test that helps physicians guide treatment for patients with non-small cell lung cancer (NSCLC).
To increase the options available to patients ... Read more